Medrio

Executive Summary

Medrio is a privately held eClinical technology company headquartered in San Francisco, founded in 2005. The company offers a unified, no-code software platform that encompasses Electronic Data Capture (EDC), ePRO/eCOA, eConsent, and RTSM, designed to streamline clinical trial data management and operations. By enabling sponsors and CROs to accelerate study timelines, improve data quality, and reduce complexity, Medrio has positioned itself as a key player in the digital health and clinical trials ecosystem. Despite being bootstrapped (with no disclosed funding or valuation), the company has maintained a steady presence in the market, leveraging its enterprise-grade, cloud-based solutions to serve a diverse client base. Medrio's platform addresses critical pain points in clinical research, such as site burden and data fragmentation, making it a compelling option for organizations seeking to modernize their trial operations. The company continues to evolve its product suite to meet regulatory demands and the shift towards decentralized and hybrid trial models.

Upcoming Catalysts (preview)

• Q3 2026Launch of AI-Powered Data Insights Module70% success
• Q4 2026Strategic Partnership with Major CRO50% success
• Q2 2026FDA 510(k) Clearance for eCOA Module80% success